Artificial intelligence will be a key driver in the global precision medicine market, which according to Global Market Insights Inc. is expected to grow to USD 87.7 billion by 2023. Brendan Frey, the CEO of Deep Genomics, was quoted in the MIT Technology Review, saying For the first time in history, our ability to measure our biology, and even to act on it, has far surpassed our ability to understand it. The only technology we have for interpreting and acting on these vast amounts of data is AI. That's going to completely change the future of medicine. The result will be more targeted therapeutics and risk reduction models, leading to better clinical decision support across disease areas.
Co-presented by SGInnovate and ACCESS Health International, a panel of experts from artificial intelligence, genomics, and healthcare will discuss how machine learning will accelerate the development of personalized medicine and change our understanding of the genome/disease/environment interface.
- Dr. Robert Morris, Professor, Yong Loo Lin School of Medicine, National University of Singapore
- Dr. Xiaoqing Liu, Director of Artificial Intelligence, Complete Genomics Inc.
- Dr. Ngeow Yuen Yie Joanne, Senior Consultant, National Cancer Centre Singapore
- Dr. Devanathan Raghunathan, Principal, Exploit Technologies Pte Ltd (ETPL)
- Dr. Mark Burby, Health and Life Sciences Director, Intel
Moderated by: Steve Leonard, Founding CEO, SGInnovate
Date: 15 March 2018
Time: 5:30pm - 7:30pm
Venue: 32 Carpenter Street, Singapore 059911
5:30pm - 6:00pm: Registration
6:00pm - 7:00pm: Health Futures - AI and Genomics panel discussion
7:00pm - 7:30pm: Q&A and Networking